New blood filter for sepsis: does it remove Life-Saving antibiotics?

NCT ID NCT06602245

Completed Knowledge-focused Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a blood-filtering device called Efferon LPS removes antibiotics from the blood of people with sepsis. Sepsis is a severe infection that can lead to organ failure, and doctors sometimes use filters to clean the blood. The study included 30 patients and measured how much antibiotic was cleared by the filter. The goal was to see if the filter might accidentally reduce antibiotic levels, which could make treatment less effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efferon LPS hemoperfusion device
What this could lead to: If successful, this could help doctors understand how to safely use the Efferon LPS device without reducing antibiotic effectiveness in sepsis patients.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply to all patients. It only measures drug clearance, not patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS SEPTIC SHOCK

Contacts and locations

Locations

N. V. Sklifosovsky Moscow Research Institute of Emergency

Moscow, Russia
N.I. Pirogov City Clinical Hospital No. 1

Moscow, Russia
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko

Nizhny Novgorod, Russia
Perm regional clinical hospital

Perm, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.